<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112738">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02049866</url>
  </required_header>
  <id_info>
    <org_study_id>AAAN0161</org_study_id>
    <nct_id>NCT02049866</nct_id>
  </id_info>
  <brief_title>Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP</brief_title>
  <official_title>Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With Idiopathic Osteoporosis: a Phase IIB Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elizabeth Shane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Creighton University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate antiresorptive therapy with denosumab
      (Prolia) for prevention of bone loss after stopping teriparatide (Forteo) in premenopausal
      women with idiopathic osteoporosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoporosis in premenopausal women with normal menstrual function and no specific cause is
      termed idiopathic osteoporosis (IOP). IOP is a rare disease with an estimated prevalence of
      &lt;200,000 affected premenopausal women in the United States.

      Investigators are currently enrolling 40 premenopausal women with IOP into a new,
      randomized, 24-month, FDA Orphan Diseases Program-funded trial, &quot;A Phase 2 Study of
      Teriparatide for the Treatment of Idiopathic Osteoporosis in Premenopausal Women&quot;
      (NCT01440803). The follow-up data from our pilot study lead the investigators to conclude
      that participants in FD003902 will require antiresorptive treatment to prevent bone loss
      after completing TPTD. Denosumab, a potent inhibitor of osteoclast-mediated bone resorption,
      leads to continuous gains in both trabecular and cortical BMD. Moreover, denosumab is not
      retained in the skeleton, and may thus be preferable for use in young women who may be
      contemplating future pregnancies. The investigators hypothesize that denosumab, initiated
      after completion of two years of TPTD, will maintain or improve central and peripheral areal
      and volumetric BMD, microstructure and stiffness in premenopausal women with IOP. The
      investigators will test this hypothesis in a 24-month study of denosumab (ProliaÂ®, 60mg SC
      every 6 months).  As planned enrollment in NCT01440803 is 40 women and some may not choose
      to participate, power is too low for a randomized, placebo-controlled design. Therefore, the
      investigators  plan an open-label, pilot study. The goals of the study are to estimate the
      effects of denosumab on central and peripheral, as well as trabecular and cortical, bone
      mass and microstructure and to obtain preliminary data to inform the design of a future
      randomized study. This study presents the first opportunity to study the effects of
      denosumab after TPTD in this unique and severely affected group of young women.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Percent change in lumbar spine areal BMD by DXA</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Adult Idiopathic Generalized Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Denosumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Denosumab 60mg, administered every 6 months by subcutaneous injection for 24 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>Denosumab 60mg, administered every 6 months by subcutaneous injection for 24 months</description>
    <arm_group_label>Denosumab</arm_group_label>
    <other_name>Prolia</other_name>
    <other_name>Xgeva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All women completing NCT01440803 who remain without a disease or medication that
             causes osteoporosis will be offered enrollment into this study.

          -  Premenopausal status will no longer be required for entry into this study.

        Exclusion Criteria:

          -  Renal insufficiency or liver disease: Creatinine, AST/ALT above upper limit of normal

          -  Vitamin D deficiency: 25-OHD&lt;30 ng/mL

          -  Pregnancy: urine pregnancy test must be negative
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Shane, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adi Cohen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emily M Stein, MD</last_name>
    <role>Study Director</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mariana Bucovsky, BA</last_name>
    <phone>212-305-7225</phone>
    <email>mb3523@columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adi Cohen, MD</last_name>
    <phone>212-342-1291</phone>
    <email>ac1044@columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Creighton University</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>402-280-4470</phone>
    </contact>
    <investigator>
      <last_name>Robert Recker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joan Lappe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>212-305-7225</phone>
    </contact>
    <investigator>
      <last_name>Elizabeth Shane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adi Cohen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emily M Stein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://columbiamedicine.org/divisions/Endo/index.shtml</url>
    <description>Columbia University, Dept of Medicine, Division of Endocrinology website</description>
  </link>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 29, 2014</lastchanged_date>
  <firstreceived_date>January 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Elizabeth Shane</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>premenopausal</keyword>
  <keyword>denosumab</keyword>
  <keyword>idiopathic</keyword>
  <keyword>Idiopathic Osteoporosis in Premenopausal Women</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
